[quote align=”center” color=”#999999″]The special design of the NIH OxCam program puts me at a tremendous advantage in leading an independent laboratory in the future. The program’s requirement for each student to design a novel collaboration between unaffiliated NIH and UK mentors has tested me from the outset to define a clear research question and to actively manage an international project. There is no other program in existence that expects this level of autonomy during the PhD. The payoff is graduating having already built a proven track record driving independent biomedical research.[/quote]
Mike graduated from Pomona College in 2011 with a degree in Chemistry as the Brackett and Stauffer scholar. He was awarded a Churchill Fellowship and completed a Masters thesis in Chemistry at University of Cambridge in the lab of Prof. Shankar Balasubramanian. Mike began in the OxCam program the following year, moving to the Department of Medicine under the same PI. He designed a collaboration with the National Center for Advancing Translational Sciences (NCATS) at NIH, under the tutelage of Drs. Anton Simeonov and Craig Thomas. The overarching theme of his research work has been the pairing of high throughput screening methodologies at NIH with state-of-the-art genomics capabilities at Cambridge in order to discover unique therapeutic sensitivities of human cancers and new modalities for treatment.
Mike’s graduate research has led to several first and lead author publications in high impact journals. In 2015 he was recognized with the Biomedical Alliance’s Innovation Award for Novel Solutions in Biology or Medicine as a result of his main thesis project. The American Association for Cancer Research (AACR) awarded Mike the Aflac Scholar-in-Training distinction for his paper submitted to the 2016 Annual Meeting. As an NIH-Cambridge MD/PhD Track 3 student, he will complete his PhD in Chemical Oncology in 2016 and matriculate to medical school.